The school of medicine at Trinity College Dublin, Ireland, has launched what it claims is the world's first academic course in high content screening and analysis
High content screening and analysisis a pioneering technology provides an information rich holistic assessment of cellular behaviour in both health and disease.
The new technology has the potential of significantly accelerating the development of more effective cures and treatments of diseases such as cancer, heart disease and infectious diseases.
In February 2007, Trinity College's department of clinical medicine launched the world's first course in high content research as part of the already established masters degree in molecular medicine.
This innovative new course was developed in collaboration with Trinity's own internationally recognised high content research facility based in St James's Hospital.
"The course was attended by approximately 30 postgraduates students from a wide range of scientific and medical disciplines," said Anthony Davies, high content research facility director, department of clinical medicine, Trinity College Dublin.
"Our students received extensive theoretical and practical tuition from world leading experts in the fields of HCA platform technologies, experimental design, robotised workflow, image and data analysis as well as the very latest techniques in team leadership training.
"The success of this Trinity College medical school initiative was made possible by the active role played by organisations such as AstraZeneca, Deerac Fluidics, Edge, GE Healthcare, Invitrogen, Perkin Elmer, Process Automation and Analysis, Thermo Fisher Scientific, TTP Labtec, Spotfire, and University College Dublin.
"We would also like to thank Yuri Volkov (HCS/A course director, dept clinical medicine, Trinity College Dublin) for his continuous support and contribution during this endeavour".
